[Infostock Daily= Reporter An Hoe Hyun] IBK Securities predicted on the 22nd that Korea Kolmar will be able to recover the momentum of domestic and Chinese operations due to the Atomy effect in the fourth quarter, although cosmetics, their main business, were sluggish at home and abroad last year.
This year, it is expected to focus on strategies to restore domestic and foreign cosmetics and link synergy with HKN for smooth HKN IPO in the future. The target stock price was raised from 60,000 won to 65,000 won, maintaining the Buy opinion.
"Korea Kolmar finalized the transfer of pharmaceutical CMO business to a private equity firm on December 28 last year," the company said and expected, "The total sale amount is 301.1 billion won, and it will improve its business capabilities by improving its financial structure and restructuring the group in the future."
As it experienced COVID-19 in 2020 with HKN's IPO planned for 2022, it is expected to highlight the stability of its business compared to the industry and speed up growth recovery in 2021.
Reporter An Hoe Hyun ahh@infostock.co.kr
